Insider Buying: Elanco Animal Health (NYSE:ELAN) Director Purchases $109,100.00 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) Director Michael Harrington purchased 5,000 shares of Elanco Animal Health stock in a transaction on Wednesday, August 12th. The shares were acquired at an average cost of $21.82 per share, for a total transaction of $109,100.00. Following the completion of the transaction, the director owned 131,451 shares of the company’s stock, valued at $2,868,260.82. This represents a 3.95% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Elanco Animal Health Price Performance

ELAN opened at $23.64 on Friday. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. Elanco Animal Health Incorporated has a 52-week low of $17.11 and a 52-week high of $27.98. The company has a 50 day moving average of $24.56 and a two-hundred day moving average of $24.02. The company has a market cap of $11.81 billion, a P/E ratio of -57.65, a P/E/G ratio of 1.42 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, analysts expect that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

Hedge Funds Weigh In On Elanco Animal Health

Institutional investors have recently added to or reduced their stakes in the company. Peak Retirement Planning Inc. acquired a new position in shares of Elanco Animal Health in the 4th quarter valued at about $2,756,000. Norges Bank acquired a new stake in Elanco Animal Health during the fourth quarter worth about $32,415,000. Robeco Institutional Asset Management B.V. acquired a new stake in Elanco Animal Health during the fourth quarter worth about $3,947,000. OP Asset Management Ltd bought a new position in Elanco Animal Health in the first quarter worth about $8,171,000. Finally, Principal Financial Group Inc. lifted its holdings in Elanco Animal Health by 7.3% in the first quarter. Principal Financial Group Inc. now owns 1,386,907 shares of the company’s stock worth $33,189,000 after acquiring an additional 94,671 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. JPMorgan Chase & Co. boosted their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Wall Street Zen lowered Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. Morgan Stanley boosted their price target on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 22nd. Finally, TD Cowen upped their price target on Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.